SAN FRANCISCO, CA, Jul 06, 2010 (MARKETWIRE via COMTEX) --
Urigen Pharmaceuticals, Inc. (OTCBB: URGP), a specialty
pharmaceutical company focused on the development of treatments for
urological disorders and pain, announced an expansion of its
management team and an FDA update. The FDA denied the company's
request for an End of Phase 2 meeting at this time, but has signaled
its willingness to meet with the company as it moves forward with the
URG101 program for Painful Bladder Syndrome/Interstitial cystitis.
The Company plans to conduct Phase IIb studies for URG101. The
Company believes that successful phase IIb studies may provide
sufficient evidence of safety and efficacy to form the clinical basis
of an NDA submission and that this plan will not delay our ultimate
Commencing today, Lowell Parsons, MD, a member of the Board of
Directors, has joined the company as Chief Medical Officer. Also, Dan
Vickery, PhD, a member of the Board of Directors, has been engaged as
a development and strategic consultant and will be increasing his
efforts in business development on the Company's behalf. In addition,
Jeffrey G. Proctor, MD, at a recent meeting of Urigen's Scientific
Advisory Board was appointed Chairman of the Scientific Advisory
Board. Dr. Proctor is Director of Interstitial Cystitis for Georgia
"Dr. Parsons developed the technology upon which Urigen was founded,"
said Urigen's CEO William J. Garner, MD. "He also invented the last
successful pharmaceutical product in our area of focus for URG101 in
the 1990's." Dr. Proctor added, "Over a career spanning decades, Dr.
Parsons has been the preeminent scientist working to solve this very
difficult clinical problem."
Lowell Parsons, who will remain Prof. Emeritus at the University of
California, San Diego, said, "I have given over 20,000 treatments on
a compassionate basis with this technology to my patients. I look
forward to working with the management team in my expanded role at
Urigen to assist in raising awareness of Painful Bladder
Syndrome/Interstitial Cystitis and advancing URG 101 to
commercialization as a solution for this."
Dr. Vickery has extensive experience in business development and
regulatory affairs. He was responsible for global urology commercial
development at Pharmacia and has built a global business development
consultancy with a focus in urology.
"I have invested in Urigen and am increasing my commitment to the
company as I see the need for URG101 in the different global
markets," said Dr. Vickery.
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company
dedicated to the development and commercialization of therapeutic
products for urological disorders. Urigen's two lead programs target
significant unmet medical needs and major market opportunities in
urology. Urigen's URG101, a proprietary combination of approved drugs
that is instilled into the bladder, targets painful bladder syndrome,
which affects approximately 10.5 million men and women in North
America. Urigen's URG301, a proprietary dosage form of an approved
drug that is locally delivered to control urinary urgency, targets
acute urgency in females diagnosed with an overactive bladder,
another major unmet need that is insufficiently managed by presently
available overactive bladder drugs. For further information, please
visit Urigen's website at http://www.urigen.com.
This press release may contain forward-looking statements. These
statements may be identified by the use of forward-looking
terminology such as "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "might," "plan," "potential,"
"predict," "should," or "will," or the negative thereof or other
variations thereon or comparable terminology. Urigen has based these
forward-looking statements on current expectations, assumptions,
estimates and projections. While Urigen believes that these
expectations, assumptions, estimates and projections are reasonable,
such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond
its control. Given these risks and uncertainties, investors and
security holders are cautioned not to place undue reliance on such
forward-looking statements. Urigen does not undertake any obligation
to update any such statements or to publicly announce the results of
any revisions to any such statements to reflect future events or
SOURCE: Urigen Pharmaceuticals, Inc.